Enbrel and Humira remain the mainstay for first-line biologic rheumatoid arthritis treatment in USA

19 September 2013

The vast majority of patients in the USA treated with Amgen's (Nasdaq: AMGN) Enbrel (etanercept) and AbbVie's (NYSE: ABBV) abatacept) Humira (adalimumab) - significantly more patients than those treated with any other non-traditional disease-modifying antirheumatic drug - were biologic-naive and, therefore, taking these agents as their first-line biologic treatment, according to BioTrends Research, a unit of Decision Resources.

Although Pfizer's (NYSE: PFE) Xeljanz ( tofacitinib) has been on the market for only about six months at the time this study was fielded, nearly 60% of rheumatoid arthritis (RA) patients currently treated with this drug were biologic-naive prior to initiation, which is in-line with its Food and Drug Administration-approved label. Xeljanz-treated patients who were previously treated with another agent were most commonly switched from Enbrel, Humira and Bristol-Myers Squibb's Orencia IV (abatacept).

81% of Xeljanz patients experienced partial or complete remission

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK